Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Berruti

Showing results (61-70 of 379) with videos related to

Pageof 38
Sort By:
Endocrine|May 18, 2022
FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinomaMariangela Tamburello, Barbara Altieri, Iuliu Sbiera, et al.
The Oncologist|August 13, 2011
Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic reviewConsuelo Buttigliero, Chiara Monagheddu, Paola Petroni, et al.
Journal of Oncology|May 7, 2019
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical CarcinomaChiara Fiorentini, Salvatore Grisanti, Deborah Cosentini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Serum Vitamin D and Prostate Cancer Prognosis: The Story ContinuesElisa Roca, Francesca Valcamonico, Vito Amoroso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?Francesca Valcamonico, Fausto Petrelli, Laura Ferrari, et al.
Expert Review of Anticancer Therapy|August 18, 2018
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management optionsSoraya Puglisi, Paola Perotti, Deborah Cosentini, et al.
Current Treatment Options in Oncology|November 18, 2023
The Evolving Treatment Landscape of Medullary Thyroid CancerMarta Laganà, Valentina Cremaschi, Andrea Alberti, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2022
Letter to the Editor From Cosentini et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival"Deborah Cosentini, Marta Laganà, Antonella Turla, et al.
The American Journal of Surgical Pathology|June 11, 2010
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behaviorMauro Papotti, Marco Volante, Eleonora Duregon, et al.
Drugs & Aging|December 24, 2002
Background to and management of treatment-related bone loss in prostate cancerAlfredo Berruti, Marcello Tucci, Carlo Terrone, et al.
Pageof 38

Showing results (61-70 of 379) with videos related to

Sort By:
Pageof 38
Endocrine|May 18, 2022
FGF/FGFR signaling in adrenocortical development and tumorigenesis: novel potential therapeutic targets in adrenocortical carcinomaMariangela Tamburello, Barbara Altieri, Iuliu Sbiera, et al.
The Oncologist|August 13, 2011
Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic reviewConsuelo Buttigliero, Chiara Monagheddu, Paola Petroni, et al.
Journal of Oncology|May 7, 2019
Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical CarcinomaChiara Fiorentini, Salvatore Grisanti, Deborah Cosentini, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
Serum Vitamin D and Prostate Cancer Prognosis: The Story ContinuesElisa Roca, Francesca Valcamonico, Vito Amoroso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2014
Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?Francesca Valcamonico, Fausto Petrelli, Laura Ferrari, et al.
Expert Review of Anticancer Therapy|August 18, 2018
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management optionsSoraya Puglisi, Paola Perotti, Deborah Cosentini, et al.
Current Treatment Options in Oncology|November 18, 2023
The Evolving Treatment Landscape of Medullary Thyroid CancerMarta Laganà, Valentina Cremaschi, Andrea Alberti, et al.
The Journal of Clinical Endocrinology and Metabolism|March 18, 2022
Letter to the Editor From Cosentini et al: "Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients' Survival"Deborah Cosentini, Marta Laganà, Antonella Turla, et al.
The American Journal of Surgical Pathology|June 11, 2010
Adrenocortical tumors with myxoid features: a distinct morphologic and phenotypical variant exhibiting malignant behaviorMauro Papotti, Marco Volante, Eleonora Duregon, et al.
Drugs & Aging|December 24, 2002
Background to and management of treatment-related bone loss in prostate cancerAlfredo Berruti, Marcello Tucci, Carlo Terrone, et al.
Pageof 38